Jackson SS, Pfeiffer RM, Liu Z, et al. - Researchers examined how postdiagnosis aspirin use influence biliary tract cancers (BTCs) survival. Using the United Kingdom’s Clinical Practice Research Datalink, an electronic medical record database, they obtained data, including all-cause deaths, on 2,934 adult patients diagnosed with BTC; of these, 667 (23%) had gallbladder cancer; 1,559 (53%) cholangiocarcinoma; 224 (8%) ampulla of Vater cancer; and 484 (16%) overlapping. At baseline 256 (9%) patients were aspirin users and after diagnosis, 349 (12%) patients, additionally, initiated aspirin use. As per outcomes, postdiagnosis aspirin users across all BTC types had a reduced risk of death. Given that tumor cells are protected from elimination, metastatic cell growth enhances and cancerous cells spread enables via the bloodstream in correlation to platelet activation. Aspirin through inhibition of platelet aggregation slows the metastatic spread of cancer cells and in turn, improves BTC survival.